This work was supported by a grant from Fulbright and the National Council of Science and Technology of Mexico (CONACYT) and a Doctoral Dissertation Fellowship from the Graduate School of the University of Minnesota as part of Dr. Alarid-Escudero's doctoral program. Drs. Kuntz and Alarid-Escudero were supported by two grants from the National Cancer Institute at the National Institutes of Health (grant numbers U01-CA-199335 and U01-CA-253913) as part of the Cancer Intervention and Surveillance Modeling Network (CISNET). The funding agencies had no role in the design of the study, interpretation of results, or writing of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. No other funding was noted.

cdx2cea is an R package that implements the cost-effectiveness analysis (CEA) of testing average-risk Stage II colon cancer patients for the absence of CDX2 biomarker expression followed by adjuvant chemotherapy. cdx2cea is part of the following manuscript: Alarid-Escudero F, Schrag D, Kuntz KM. (2021) “CDX2 biomarker testing and adjuvant therapy for stage II colon cancer: An exploratory cost-effectiveness analysis” Value in Health (In press).